Die chronisch obstruktive Lungenerkrankung (COPD)
Grundlagen, Risikofaktoren und Diagnose

Lerninhalte

Grundlagenwissen zu Definition, Epidemiologie, Ätiologie und sozialökonomischer Bedeutung der COPD. Pathogenese, Pathologie, klinischer Verlauf und Klassifikation der stabilen COPD. Diagnose und Differenzialdiagnose der COPD. Differenzierte Beschreibung der diagnostischen Methoden und ihre Anwendung.

Literatur

• 1 Worth H, Buhl R, Cegla U. et al . Leitlinien der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD).  Pneumologie. 2002;  56 704-738
• 2 Pauwels R A, Buist A S, Calverley P MA. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  163 1256-1276
• 3 Lopez A D, Murray C JL. The global burden of disease, 1990 - 2020.  Nature Med. 1998;  4 1241-1243
• 4 Statistisches Bundesamt .Statistisches Jahrbuch, Jahrgänge 1968 - 1999. Stuttgart-Mainz
• 5 Konietzko N, Fabel H. Weißbuch Lunge,. Stuttgart-New York: Thieme 2000
• 6 Rychlik R, Pfeil T, Daniel D. et al . Zur sozioökonomischen Relevanz akuter Exacerbationen der chronischen Bronchitis in der Bundesrepublik Deutschland.  Dtsch Med Wschr. 2001;  126 353-359
• 7 Groneberg D A, Chung K F. Models of chronic obstructive pulmonary disease.  Respir Res. 2004;  5 18-34
• 8 Wolkove N, Dacezman E, Colacone A. et al . The relationship between pulmonary function and dyspnoea in obstructive lung disease.  Chest. 1989;  96 1247-1251
• 9 Begin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1991;  143 901-903
• 10 O'Donnell D E, Forkert L, Webb K A. Evaluation of bronchodilator responses in patients with “irreversible” emphysema.  Eur Respir J. 2001;  18 914-920
• 11 Baldi S, Miniati M, Bellina C R. et al . Relationship between extent of pulmonary emphysema by high-resolution computed tomography and lung elastic recoil in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  169 585-589
• 12 Georgopoulos D, Anthonisen N R. Symptoms and signs of COPD. In: Cherniack NS (ed). Chronic obstructive pulmonary disease. Toronto: Saunders 1991: 357-363
• 13 Seemungal T A, Donaldson G C, Bhownik A. et al . Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2000;  161 1608-1613
• 14 Groneberg D A, Witt C, Kage A. O₂-Partialdruck im Blut. In: Sinha P (ed). Laborbefunde und ihre klinischen Interpretationen. Balingen: Spitta Verlag
• 15 Groneberg D A, Witt C, Kage A. CO₂-Partialdruck im Blut. In: Sinha P (ed). Laborbefunde und ihre klinischen Interpretationen. Balingen: Spitta Verlag
• 16 Roberts C M, Bugler J R, Melchor R. et al . Value of pulse oximetry for long-term oxygen therapy requirement.  Eur Respir J. 1993;  6 559-562
• 17 Groneberg D A, Witt C, Kage A. O₂-Sättigung im Blut. In: Sinha P (ed). Laborbefunde und ihre klinischen Interpretationen. Balingen: Spitta Verlag
• 18 Hughes J MB, Pride N B. In defense of the carbon monoxide transfer coefficent Kco(TL/VA).  Eur Respir J. 2001;  17 168-174
• 19 Gould G A, Redpath A T, Ryan M. et al . Lung CT density correlates with measurements of airflow limitation and the diffusing capacity.  Eur Respir J. 1991;  4 141-146
• 20 Gevenois P A, de Vuyst P, de Maertelaer V. et al . Comparison of computed density and microscopic morphometry in pulmonary emphysema.  Am J Respir Crit Care Med. 1996;  154 187-192
• 21 McLean A, Warren P M, Gilooly M. et al . Microscopic and macroscopic measurement of emphysema: relation to carbon monoxide transfer.  Thorax. 1992;  47 14-19
• 22 Thurlbeck W M, Simon G. Radiographic appearance of the chest in emphysemas.  Am J Roentgenol. 1978;  130 429-440
• 23 Morgan M DL, Denison D M, Stricklund B. Value of computed tomography for selecting patients with bullous emphysema.  Thorax. 1986;  41 855-862
• 24 O'Donnell D E, Lam M, Webb K A. Spirometric correlates for improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1999;  160 542-549
• 25 Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago “COPD” series.  Am Rev Respir Dis. 1989;  140 92-94
• 26 Traver G A, Cline M G, Burrows B. Predictors of mortality in COPD.  Am Rev Respir Dis. 1979;  119 895-902
• 27 Tweeddale P W, Alexander F, McHardy G JR. Short term variability in FEV₁ and bronchodilator responsiveness in patients with obstructive ventilatory defects.  Thorax. 1987;  42 87-90
• 28 Quanjer P H. Standardised lung function testing. Official statement of the European Respiratory Society.  Eur Respir J. 1993;  6 (Suppl 16) 5-40
• 29 Berger R, Smith D. Effect of an inhaled metaproterenol on exercise performance in patients with stable “fixed” airway obstruction.  Am Rev Respir Dis. 1988;  138 626-629
• 30 Guyatt G H, Townsend M, Pugsley S O. et al . Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity and quality of life.  Am Rev Respir Dis. 1987;  135 1069-1074
• 31 Gross N, Tashkin D, Miller R. et al . Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.  Respiration. 1998;  65 354-362
• 32 Guyatt G H, Townsend M, Nogradi S. et al . Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation.  Arch Intern Med. 1988;  148 1949-1952
• 33 Callahan C M, Cirrus R S, Katz B P. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis.  Ann Intern Med. 1991;  114 216-223
• 34 Worth H, Adam D, Handrick W. et al . Prophylaxe und Therapie von bronchopulmonalen Infektionen. Empfehlungen der Deutschen Atemwegsliga.  Pneumologie. 1998;  52 232-237
• 35 Niedermeier J, Barner A, Borst M. et al . Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Anwendung der Echokardiographie in der pneumologischen Diagnostik.  Pneumologie. 1998;  52 519-521
• 36 Lehtonen J, Sutinen S, Ikaheimo M. et al . Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified at autopsy.  Chest. 1988;  93 839-842
• 37 Cohen B, Ball Jr W, Brashears S. et al . Risk factors in chronic obstructive pulmonary disease (COPD).  Am J Epidemiol. 1977;  105 223-232
• 38 Cohen B, Bias W, Chase G. et al . Is ABH nonsecretor status a risk factor for obstructive lung disease?.  Am J Epidemiol. 1980;  111 285-291
• 39 Kauffmann F, Frette C, Pham Q. et al . Associations of blood group-related antigens to FEV₁, wheezing, and asthma.  Am J Respir Crit Care Med. 1996;  153 76-82
• 40 Tobin M J, Cook P J, Hutchison D C. α1-antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association.  Br J Dis Chest. 1983;  77 14-27
• 41 Larsson C. Natural history and life expectancy in severe α1-antitrypsin deficiency, Pi Z.  Acta Med Scand. 1978;  204 345-351
• 42 Piitulainen E, Eriksson S. Decline in FEV₁ related to smoking status in individuals with severe α1-antitrypsin deficiency (PiZZ).  Eur Respir J. 1999;  13 247-251
• 43 Silverman E K, Pierce J A, Province M A. et al . Variability of pulmonary function in α1-antitrypsin deficiency: clinical correlates.  Ann Intern Med. 1989;  111 982-991
• 44 Silverman E K, Province M A, Campbell E J. et al . Family study of α1-antitrypsin deficiency: effects of cigarette smoking, measured genotype, and their interaction on pulmonary function and biochemical traits.  Genet Epidemiol. 1992;  9 317-331
• 45 Seersholm N, Kok-Jensen A, Dirksen A. Decline in FEV₁ among patients with severe hereditary α1-antitrypsin deficiency type PiZ.  Am J Respir Crit Care Med. 1995;  152 1922-1925
• 46 Seersholm N, Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary α1-antitrypsin deficiency.  Am J Respir Crit Care Med. 1995;  151 369-373
• 47 Black L F, Kueppers F. α1-Antitrypsin deficiency in nonsmokers.  Am Rev Respir Dis. 1978;  117 421-428
• 48 Piitulainen E, Tornling G, Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe α1-antitrypsin deficiency (PiZZ).  Thorax. 1998;  53 939-943
• 49 Mayer A S, Stoller J K, Bartelson B B. et al . Occupational Exposure Risks in Individuals with PI*Z α-1-Antitrypsin Deficiency.  Am J Respir Crit Care Med. 2000;  162 553-558
• 50 Benetazzo M G, Gile L S, Bombieri C. et al . α-1-antitrypsin TAQ I polymorphism and α-1-antichymotrypsin mutations in patients with obstructive pulmonary disease.  Respir Med. 1999;  93 648-654
• 51 Poller W, Faber J P, Scholz S. et al . Missense mutation of α-1-antichymotrypsin gene associated with chronic lung disease.  Lancet. 1992;  339 1538
• 52 Sandford A J, Chagani T, Weir T D. et al . α-1-antichymotrypsin mutations in patients with chronic obstructive pulmonary disease.  Dis Markers. 1998;  13 257-260
• 53 Ishii T, Matsuse T, Teramoto S. et al . Association between α-1-antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary disease.  Eur J Clin Invest. 2000;  30 543-548
• 54 Minematsu N, Nakamura H, Iwata M. et al . Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema.  Thorax. 2003;  58 623-628
• 55 Pignatti P F, Bombieri C, Benetazzo M. et al . CFTR gene variant IVS8 - 5T in disseminated bronchiectasis.  Am J Hum Genet. 1996;  58 889-892
• 56 Bombieri C, Benetazzo M, Saccomani A. et al . Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease.  Hum Genet. 1998;  103 718-722
• 57 Tzetis M, Efthymiadou A, Strofalis S. et al . CFTR gene mutations - including three novel nucleotide substitutions - and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease.  Hum Genet. 2001;  108 216-221
• 58 Yim J-J, Park G Y, Lee C-T. et al . Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1.  Thorax. 2000;  55 121-125
• 59 Harrison D J, Cantlay A M, Rae F. et al . Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer.  Hum Exp Toxicol. 1997;  16 356-360
• 60 Baranova H, Perriot J, Albuisson E. et al . Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis.  Hum Genet. 1997;  99 822-826
• 61 Ishii T, Matsuse T, Teramoto S. et al . Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease.  Thorax. 1999;  54 693-696
• 62 Yamada N, Yamaya M, Okinaga S. et al . Microsatellite polymorphism in the heme oxygenase-1-gene promoter is associated with susceptibility to emphysema.  Am J Hum Genet. 2000;  66 187-195
• 63 Kauffmann F, Kleisbauer J P, Cambon-De-Mouzon A. et al . Genetic markers in chronic air-flow limitation. A genetic epidemiologic study.  Am Rev Respir Dis. 1983;  127 263-269
• 64 Sugiyama Y, Kudoh S, Maeda H. et al . Analysis of HLA antigens in patients with diffuse panbronchiolitis.  Am Rev Respir Dis. 1990;  141 1459-1462
• 65 Keicho N, Tokunaga K, Nakata K. et al . Contribution of HLA Genes to Genetic Predisposition in Diffuse Panbronchiolitis.  Am J Respir Crit Care Med. 1998;  158 846-850
• 66 Bjorkander J, Bake B, Oxelius V. et al . Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3.  N Engl J Med. 1985;  313 720-724
• 67 O'Keeffe S, Gzel A, Drury R. et al . Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease.  Eur Respir J. 1991;  4 932-936
• 68 Webb D R, Condemi J J. Selective immunoglobulin A deficiency and chronic obstructive lung disease. A family study.  Ann Intern Med. 1974;  80 618-621
• 69 Smith C A, Harrison D J. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema.  Lancet. 1997;  350 630-633
• 70 Yoshikawa M, Hiyama K, Ishioka S. et al . Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese.  Int J Mol Med. 2000;  5 49-53
• 71 Sandford A J, Chagani T, Weir T D. et al . Susceptibility Genes for Rapid Decline of Lung Function in the Lung Health Study.  Am J Respir Crit Care Med. 2001;  163 469-473
• 72 Bouma G, Crusius J B, Oudkerk Pool M. et al . Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease.  Scand J Immunol. 1996;  43 456-463
• 73 Huang S-L, Su C-H, Chang S-C. Tumor Necrosis Factor-alpha Gene Polymorphism in Chronic Bronchitis.  Am J Respir Crit Care Med. 1997;  156 1436-1439
• 74 Sakao S, Tatsumi K, Igari H. et al . Association of Tumor Necrosis Factor {α} Gene Promoter Polymorphism with the Presence of Chronic Obstructive Pulmonary Disease.  Am J Respir Crit Care Med. 2001;  163 420-422
• 75 Ishii T, Matsuse T, Teramoto S. et al . Neither IL-1β, IL-1 receptor antagonist, nor TNF-α polymorphisms are associated with susceptibility to COPD.  Respir Med. 2000;  94 847-851
• 76 Higham M A, Pride N B, Alikhan A. et al . Tumour necrosis factor-α gene promoter polymorphism in chronic obstructive pulmonary disease.  Eur Respir J. 2000;  15 281-284
• 77 Horne S L, Cockcroft D W, Dosman J A. Possible protective effect against chronic obstructive airways disease by the GC2 allele.  Hum Hered. 1990;  40 173-176
• 78 Schellenberg D, Pare P D, Weir T D. et al . Vitamin D Binding Protein Variants and the Risk of COPD.  Am J Respir Crit Care Med. 1998;  157 957-961
• 79 Springer J, Scholz F R, Peiser C. et al . SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitory SMAD 6 and 7 by cigarette smoke.  Biol Chem. 2004;  385 649-653